Concepts (57)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dermatitis, Atopic | 2 | 2018 | 47 | 0.670 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2017 | 11 | 0.560 |
Why?
|
| Phosphodiesterase 4 Inhibitors | 1 | 2017 | 5 | 0.560 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 396 | 0.460 |
Why?
|
| Infant Mortality | 1 | 2024 | 179 | 0.200 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2024 | 176 | 0.200 |
Why?
|
| Neonatal Screening | 1 | 2024 | 192 | 0.190 |
Why?
|
| Infant, Premature, Diseases | 1 | 2024 | 252 | 0.190 |
Why?
|
| Biliary Atresia | 1 | 2024 | 206 | 0.180 |
Why?
|
| Machine Learning | 1 | 2024 | 345 | 0.170 |
Why?
|
| Boron Compounds | 1 | 2017 | 34 | 0.140 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2017 | 83 | 0.140 |
Why?
|
| Administration, Topical | 1 | 2017 | 140 | 0.140 |
Why?
|
| United States Food and Drug Administration | 1 | 2017 | 160 | 0.130 |
Why?
|
| Skin | 1 | 2018 | 527 | 0.120 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 672 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 1246 | 0.100 |
Why?
|
| Transcriptome | 1 | 2018 | 1122 | 0.090 |
Why?
|
| Soot | 1 | 2010 | 14 | 0.090 |
Why?
|
| Ferric Compounds | 1 | 2010 | 41 | 0.080 |
Why?
|
| Metal Nanoparticles | 1 | 2010 | 56 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 3087 | 0.080 |
Why?
|
| Prognosis | 1 | 2017 | 5007 | 0.070 |
Why?
|
| Quality of Life | 1 | 2017 | 2158 | 0.070 |
Why?
|
| Epithelial Cells | 1 | 2010 | 903 | 0.060 |
Why?
|
| Bilirubin | 1 | 2024 | 128 | 0.050 |
Why?
|
| Morbidity | 1 | 2024 | 256 | 0.050 |
Why?
|
| ROC Curve | 1 | 2024 | 600 | 0.050 |
Why?
|
| United States | 1 | 2017 | 11648 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2017 | 12994 | 0.050 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2024 | 211 | 0.040 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2024 | 248 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2024 | 8542 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2024 | 2140 | 0.040 |
Why?
|
| Male | 3 | 2024 | 64872 | 0.040 |
Why?
|
| Infant, Premature | 1 | 2024 | 843 | 0.040 |
Why?
|
| Female | 3 | 2024 | 70586 | 0.040 |
Why?
|
| Algorithms | 1 | 2024 | 1720 | 0.030 |
Why?
|
| Humans | 5 | 2024 | 131929 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2018 | 353 | 0.030 |
Why?
|
| Child | 1 | 2017 | 25761 | 0.030 |
Why?
|
| Age of Onset | 1 | 2018 | 622 | 0.030 |
Why?
|
| Adult | 1 | 2017 | 31538 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1284 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1881 | 0.020 |
Why?
|
| Ascorbic Acid | 1 | 2010 | 76 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2010 | 436 | 0.020 |
Why?
|
| Biomarkers | 1 | 2018 | 3405 | 0.020 |
Why?
|
| Lysosomes | 1 | 2010 | 261 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2010 | 234 | 0.020 |
Why?
|
| Cell Survival | 1 | 2010 | 866 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2010 | 516 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2024 | 17374 | 0.020 |
Why?
|
| Cell Line | 1 | 2010 | 2718 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2010 | 2507 | 0.010 |
Why?
|
| Infant | 1 | 2018 | 13047 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2018 | 14732 | 0.010 |
Why?
|